Highlights from the Medivir R&D-Day currently underway
Medivir (OME: MVIRB SS) is, this afternoon, holding an R&D-Day in Stockholm. The objective is to provide an update on Medivir’s projects, strategy and business focus during 2008. Also being addressed are the status of two clinical phase pharmaceutical projects which Medivir itself is managing, Lipsovir® for labial (oral) herpes and MIV-701 for bone-related disorders.All presentations from the Investment Market Day will be available from 6 pm today on Medivir’s website under the tab IR-Media / Latest Presentations /Medivir R&D Day.Phase III clinical trial program for Lipsovir® proceeding